Johns Hopkins Drug Triggers 18-Fold Immune Response in 90% of High-Risk Pancreatic Patients
Updated
Updated · Good News Network · Aug 20
Johns Hopkins Drug Triggers 18-Fold Immune Response in 90% of High-Risk Pancreatic Patients
3 articles · Updated · Good News Network · Aug 20
Summary
Twenty high-risk participants in a Phase 1 trial received four doses over 13 weeks, and 18 developed mutant KRAS-specific T-cell responses without any treatment-related severe side effects.
Those responses showed a median 18-fold increase and persisted for 2 years, suggesting the vaccine-like drug can train the immune system to recognize KRAS-mutant cells before they become cancer.
After a median 16.5 months of follow-up, none of the participants developed pancreatic cancer or a high-risk lesion requiring surgery, though researchers said the study was not designed to prove prevention.
KRAS mutations appear in most pancreatic cancers and many precancerous lesions, giving the approach a potential prevention window in a disease with among the lowest survival rates.
The team previously tested the KRAS-targeting treatment in post-surgery patients in 2020; a 2026 report said strong responders remained disease-free for at least 5 years.
While the mKRAS-VAX therapy shows promise, will the immune system eventually exhaust before stopping long-term pancreatic cancer development?
If an experimental vaccine can shrink precancerous cysts, could we soon eradicate hereditary pancreatic cancer before it even begins?
First-in-Human mKRAS-VAX Vaccine Achieves 90% Immune Response and 37.5% Cyst Regression in High-Risk Pancreatic Cancer: Phase 1 Results and the Future of Immunoprevention
Overview
The mKRAS-VAX vaccine marks a major advance in pancreatic cancer prevention, showing that an off-the-shelf peptide vaccine can safely trigger strong and lasting immune responses in high-risk patients. In a Phase 1 trial, 90% of participants developed mutant KRAS-targeted T cells, which remained detectable for up to two years. Notably, over a third of patients saw their precancerous pancreatic cysts shrink or disappear, providing the first clinical proof that a vaccine can intercept cancer before it develops. With no severe side effects and a design that allows mass production, mKRAS-VAX is now moving into larger trials, supported by academic and industry partnerships.